In an interview with Targeted Oncology, Eric Jonasch, MD, discussed the impact belzutifan has had on the VHL-assocaited renal cell carcinoma space, along with unmet clinical needs the agent is addressing.
The FDA has approved adjuvant pembrolizumab for the treatment of renal cell carcinoma with an intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions.
A significant reduction in the number of patients experiencing grade 3 or 4 toxicity was observed with modified dosing as ipilimumab combine with nivolumab in patients with advanced renal cell carcinoma.
The combination of lenvatinib and pembrolizumab is the current standard of care for ccRCC, however, most patients still experience disease progression. The addition of a third agent may lead to improvement in outcomes.